Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-009486

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Warren L. DeSouza
Officer — Chief Financial Officer
Period of report
Apr 3, 2017
Accepted (ET)
Apr 5, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueApr 3, 2017M15,000$3.022A35,681D
Common Stock, $0.0001 par valueF2Apr 3, 2017S15,000$21.5824D20,681D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F3$3.022Apr 3, 2017M15,000D—May 13, 2025Common Stock15,000303,794D

Explanation of responses